Deepak L Bhatt

Summary

Affiliation: Massachusetts Institute of Technology
Country: USA

Publications

  1. ncbi request reprint Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events
    Deepak L Bhatt
    Cleveland Clinic, Cleveland, USA
    N Engl J Med 354:1706-17. 2006
  2. ncbi request reprint Real-world bare metal stenting: identification of patients at low or very low risk of 9-month coronary revascularization
    Stephen G Ellis
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Catheter Cardiovasc Interv 63:135-40. 2004
  3. doi request reprint Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromes
    Deepak L Bhatt
    VA Boston Healthcare System and Brigham and Women s Hospital, Boston, MA, USA
    Eur Heart J 30:1195-202. 2009
  4. ncbi request reprint Aspirin and platelet adenosine diphosphate receptor antagonists in acute coronary syndromes and percutaneous coronary intervention: role in therapy and strategies to overcome resistance
    Jeremiah P Depta
    Department of Internal Medicine, Cleveland Clinic, Cleveland, Ohio, USA
    Am J Cardiovasc Drugs 8:91-112. 2008
  5. ncbi request reprint Effectiveness and safety of bivalirudin during percutaneous coronary intervention in a single medical center
    Hitinder S Gurm
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am J Cardiol 95:716-21. 2005
  6. doi request reprint Comparison of drug-eluting stents versus bare-metal stents for treating ST-segment elevation myocardial infarction
    Mehdi H Shishehbor
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio, USA
    JACC Cardiovasc Interv 1:227-32. 2008
  7. doi request reprint Temporal trends and predictors in the use of aldosterone antagonists post-acute myocardial infarction
    Andrew N Rassi
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio, USA
    J Am Coll Cardiol 61:35-40. 2013
  8. ncbi request reprint Updated Strategies and Therapies for Reducing Ischemic and Vascular Events (STRIVE) ST-segment elevation myocardial infarction critical pathway toolkit
    Christopher P Cannon
    TIMI Study Group, Brigham and Women s Hospital, Boston, MA 02115, USA
    Crit Pathw Cardiol 7:223-31. 2008
  9. ncbi request reprint Arteriotomy closure device safety after percutaneous coronary intervention in the direct thrombin inhibitor era: a comparative study
    Gus Theodos
    Cleveland Clinic, Cleveland, Ohio 44195, USA
    Catheter Cardiovasc Interv 81:294-300. 2013
  10. ncbi request reprint Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet f
    Andrew L Frelinger
    Center for Platelet Research Studies, Division of Hematology Oncology, Boston Children s Hospital, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    J Am Coll Cardiol 61:872-9. 2013

Detail Information

Publications129 found, 100 shown here

  1. ncbi request reprint Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events
    Deepak L Bhatt
    Cleveland Clinic, Cleveland, USA
    N Engl J Med 354:1706-17. 2006
    ..Dual antiplatelet therapy with clopidogrel plus low-dose aspirin has not been studied in a broad population of patients at high risk for atherothrombotic events...
  2. ncbi request reprint Real-world bare metal stenting: identification of patients at low or very low risk of 9-month coronary revascularization
    Stephen G Ellis
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Catheter Cardiovasc Interv 63:135-40. 2004
    ..Conversely, if the benefits of DESs are attenuated in routine practice, many groups of patients treated with BMSs may have nearly comparable results...
  3. doi request reprint Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromes
    Deepak L Bhatt
    VA Boston Healthcare System and Brigham and Women s Hospital, Boston, MA, USA
    Eur Heart J 30:1195-202. 2009
    ....
  4. ncbi request reprint Aspirin and platelet adenosine diphosphate receptor antagonists in acute coronary syndromes and percutaneous coronary intervention: role in therapy and strategies to overcome resistance
    Jeremiah P Depta
    Department of Internal Medicine, Cleveland Clinic, Cleveland, Ohio, USA
    Am J Cardiovasc Drugs 8:91-112. 2008
    ..Noncompliance remains the most prominent mode of resistance. Screening of selected patient populations for resistance or pharmacologic intervention of those patients termed 'resistant' warrants further study...
  5. ncbi request reprint Effectiveness and safety of bivalirudin during percutaneous coronary intervention in a single medical center
    Hitinder S Gurm
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am J Cardiol 95:716-21. 2005
    ....
  6. doi request reprint Comparison of drug-eluting stents versus bare-metal stents for treating ST-segment elevation myocardial infarction
    Mehdi H Shishehbor
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio, USA
    JACC Cardiovasc Interv 1:227-32. 2008
    ..We sought to examine the clinical outcomes of patients treated with drug-eluting stents (DES) compared with bare-metal stents (BMS) during primary angioplasty for ST-segment elevation myocardial infarction (STEMI)...
  7. doi request reprint Temporal trends and predictors in the use of aldosterone antagonists post-acute myocardial infarction
    Andrew N Rassi
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio, USA
    J Am Coll Cardiol 61:35-40. 2013
    ..This study explored temporal trends in the use of aldosterone antagonist therapy among eligible patients with post-acute myocardial infarction (AMI) and reduced ejection fraction and characteristics associated with use in clinical practice...
  8. ncbi request reprint Updated Strategies and Therapies for Reducing Ischemic and Vascular Events (STRIVE) ST-segment elevation myocardial infarction critical pathway toolkit
    Christopher P Cannon
    TIMI Study Group, Brigham and Women s Hospital, Boston, MA 02115, USA
    Crit Pathw Cardiol 7:223-31. 2008
    ..The updated STEMI tools are available to clinicians online on the STRIVE Website...
  9. ncbi request reprint Arteriotomy closure device safety after percutaneous coronary intervention in the direct thrombin inhibitor era: a comparative study
    Gus Theodos
    Cleveland Clinic, Cleveland, Ohio 44195, USA
    Catheter Cardiovasc Interv 81:294-300. 2013
    ..To investigate the safety and risk of vascular complications of arteriotomy closure devices (ACD) with the direct thrombin inhibitor bivalirudin in patients undergoing percutaneous coronary intervention (PCI)...
  10. ncbi request reprint Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet f
    Andrew L Frelinger
    Center for Platelet Research Studies, Division of Hematology Oncology, Boston Children s Hospital, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    J Am Coll Cardiol 61:872-9. 2013
    ..This study sought to determine whether known genetic, drug, dietary, compliance, and lifestyle factors affecting clopidogrel absorption and metabolism fully account for the variability in clopidogrel pharmacokinetics and pharmacodynamics...
  11. ncbi request reprint Patient characteristics associated with the choice of triple antithrombotic therapy in acute coronary syndromes
    Jeremiah P Depta
    Department of Internal Medicine Medicine Institute, Cleveland Clinic, Ohio, USA
    Am J Cardiol 104:1171-8. 2009
    ..In conclusion, for patients with ACS, atrial fibrillation and atrial flutter were most strongly associated with the use of triple therapy; however, this therapy was used less often than dual or single antiplatelet therapy...
  12. ncbi request reprint Culprit-only or multivessel revascularization in patients with acute coronary syndromes: an American College of Cardiology National Cardiovascular Database Registry report
    Sorin J Brener
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH 44195, USA
    Am Heart J 155:140-6. 2008
    ..Although an early invasive strategy improves outcome in these patients, there are limited data on culprit-only, single-vessel (SV) percutaneous coronary intervention (PCI) or MV PCI in the NSTE ACS setting...
  13. ncbi request reprint Revisiting optimal anticoagulation with unfractionated heparin during coronary stent implantation
    Sorin J Brener
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am J Cardiol 92:1468-71. 2003
    ..3%, 7.5%, 8.1%, and 7.1%, respectively (p=0.71). The incidence of bleeding complications was 6.6%, 5.9%, 6.9%, and 7.3%, respectively (p=0.81). ACT did not independently predict either ischemic or hemorrhagic complications...
  14. ncbi request reprint Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial
    Deepak L Bhatt
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio 44195, USA
    J Am Coll Cardiol 49:1982-8. 2007
    ..The purpose of this study was to determine the possible benefit of dual antiplatelet therapy in patients with prior myocardial infarction (MI), ischemic stroke, or symptomatic peripheral arterial disease (PAD)...
  15. doi request reprint Current use of aspirin and antithrombotic agents in the United States among outpatients with atherothrombotic disease (from the REduction of Atherothrombosis for Continued Health [REACH] Registry)
    Christopher P Cannon
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Am J Cardiol 105:445-52. 2010
    ..In conclusion, approximately 1/4 of US patients with vascular disease are not treated with aspirin for secondary prevention, and 15% are not treated with any antithrombotic agent...
  16. doi request reprint Regional and practice variation in adherence to guideline recommendations for secondary and primary prevention among outpatients with atherothrombosis or risk factors in the United States: a report from the REACH Registry
    Amit Kumar
    Department of Hospital Medicine, University of Massachusetts Medical School, Worcester, MA, USA
    Crit Pathw Cardiol 8:104-11. 2009
    ..Few data are available for outpatients in actual clinical practice, especially those without known heart disease treated by physicians trained in different specialties across the geographic regions of the United States...
  17. doi request reprint Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis
    Deepak L Bhatt
    VA Boston Healthcare System, Brigham and Women s Hospital, and Harvard Medical School, Boston, Massachusetts 02132, USA
    JAMA 304:1350-7. 2010
    ..Prior ischemic events, polyvascular disease, and diabetes mellitus have all been identified as predictors of ischemic events, but their comparative contributions to future risk remain unclear...
  18. ncbi request reprint An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial
    Thomas H Wang
    Cleveland Clinic, Cleveland, OH, USA
    Eur Heart J 28:2200-7. 2007
    ..aspirin alone in the prespecified 'asymptomatic' subgroup of CHARISMA, we investigated whether dual-antiplatelet therapy may be associated with adverse cardiovascular (CV) events in a primary prevention population...
  19. doi request reprint Ethnic differences in the prevalence and treatment of cardiovascular risk factors in US outpatients with peripheral arterial disease: insights from the reduction of atherothrombosis for continued health (REACH) registry
    Telly A Meadows
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, USA
    Am Heart J 158:1038-45. 2009
    ..Prior investigations to define ethnic-related differences in the risks, medical treatment, and outcomes of patients with peripheral arterial disease (PAD) have been limited...
  20. doi request reprint Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin–Acute Coronary Syndromes Trial
    Michelle L O'Donoghue
    Brigham and Women s Hospital, Boston, MA 02115, USA
    Circulation 123:1843-53. 2011
    ..The primary objective of the Lessons From Antagonizing the Cellular Effects of Thrombin-Acute Coronary Syndromes (LANCELOT—ACS) trial was to evaluate the safety and tolerability of atopaxar in patients with ACS...
  21. doi request reprint Association of hospital primary angioplasty volume in ST-segment elevation myocardial infarction with quality and outcomes
    Dharam J Kumbhani
    Cleveland Clinic, Cleveland, Ohio, USA
    JAMA 302:2207-13. 2009
    ..Earlier studies indicate an inverse relationship between hospital volume and mortality after primary angioplasty for patients presenting with ST-segment elevation myocardial infarction (STEMI). However, contemporary data are lacking...
  22. ncbi request reprint Use of platelet glycoprotein IIb/IIIa inhibitors in saphenous vein graft percutaneous coronary intervention and clinical outcomes
    Juhana Karha
    The Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Am J Cardiol 98:906-10. 2006
    ..92, 95% confidence interval 0.69 to 1.23, p = 0.59). In conclusion, adjunctive use of platelet GP IIb/IIIa inhibitors in saphenous vein graft PCI does not appear to be associated with less myonecrosis or improved survival...
  23. ncbi request reprint In unstable angina or non-ST-segment acute coronary syndrome, should patients with multivessel coronary artery disease undergo multivessel or culprit-only stenting?
    Mehdi H Shishehbor
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio, USA
    J Am Coll Cardiol 49:849-54. 2007
    ....
  24. doi request reprint Quality of care and outcomes for in-hospital ischemic stroke: findings from the National Get With The Guidelines-Stroke
    Ethan Cumbler
    From the Department of Medicine, University of Colorado School of Medicine Anschutz Medical Campus, Aurora, CO E C, H W VA Boston Healthcare System, Brigham and Women s Hospital, and Harvard Medical School, Boston, MA D L B Duke Clinical Research Institute, Duke University Medical Center, Durham, NC M C, Y X Department of Epidemiology, Michigan State University, East Lansing, MI M R Department of Clinical Neurosciences, Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada E E S Department of Neurology, Massachusetts General Hospital, Boston, MA L S and Division of Cardiology, Ronald Reagan UCLA Medical Center, Los Angeles, CA G C F
    Stroke 45:231-8. 2014
    ..This study compares patient characteristics, process measures of quality, and outcomes for in-hospital strokes with those for community-onset strokes in a national cohort...
  25. doi request reprint Relationship between sex, ejection fraction, and B-type natriuretic peptide levels in patients hospitalized with heart failure and associations with inhospital outcomes: findings from the Get With The Guideline-Heart Failure Registry
    EILEEN M HSICH
    College of Medicine, Cleveland Clinic, Cleveland, OH Electronic address
    Am Heart J 166:1063-1071.e3. 2013
    ..We sought to evaluate the relationship between sex, EF, and BNP in HF patients and determine prognostic significance of BNP as it relates to sex and EF...
  26. ncbi request reprint Clopidogrel is associated with better in-hospital and 30-day outcomes than ticlopidine after coronary stenting
    Philippe L L'Allier
    Department of Cardiology, The Cleveland Clinic Foundation, Cleveland, USA
    Can J Cardiol 19:1041-6. 2003
    ..Most studies have demonstrated similar outcomes and a more favourable safety profile supporting this change in practice patterns...
  27. doi request reprint Atopaxar and its effects on markers of platelet activation and inflammation: results from the LANCELOT CAD program
    Michelle L O'Donoghue
    Cardiovascular Division and TIMI Study Group, Brigham and Women s Hospital, 350 Longwood Avenue, 1st Floor, Boston, MA 02115, USA
    J Thromb Thrombolysis 34:36-43. 2012
    ..Although atopaxar increased the concentration of Lp-PLA(2) and IL-18, the clinical relevance of these findings remains unknown and warrants further investigation and validation...
  28. doi request reprint Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective
    David P Faxon
    Division of Cardiology, Brigham and Women s Hospital, 1620 Tremont Street, OBC 3 12J, Boston, MA 02120, USA
    Thromb Haemost 106:572-84. 2011
    ....
  29. doi request reprint Bare metal stent thrombosis 13 years after implantation
    Michael L Sarkees
    Cleveland Clinic, Cleveland, OH, USA
    Cardiovasc Revasc Med 10:58-9. 2009
    ..Angiography demonstrated thrombotic occlusion and severe underlying restenosis of the stent. To our knowledge, this is the latest bare metal stent thrombosis described in the world medical literature...
  30. ncbi request reprint The combination of enoxaparin, glycoprotein IIb/IIIa inhibitors and an early invasive approach among acute coronary syndrome patients
    David S Lee
    Cleveland Clinic Foundation, Department of Cardiovascular Medicine, Desk F25, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    J Invasive Cardiol 16:46-51. 2004
    ....
  31. ncbi request reprint Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
    Benjamin M Scirica
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, and Harvard Medical School, Boston, USA
    N Engl J Med 369:1317-26. 2013
    ..The cardiovascular safety and efficacy of many current antihyperglycemic agents, including saxagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, are unclear...
  32. ncbi request reprint Quality of care and outcomes among patients with acute myocardial infarction by level of kidney function at admission: report from the get with the guidelines coronary artery disease program
    Samip Vasaiwala
    Division of Cardiology, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Clin Cardiol 35:541-7. 2012
    ..We studied the impact of chronic renal insufficiency on mortality and quality of inpatient care for AMI from the American Heart Association's Get With The Guidelines-Coronary Artery Disease Program...
  33. doi request reprint The effect of drug-eluting stents on intermediate angiographic and clinical outcomes in diabetic patients: insights from randomized clinical trials
    Dharam J Kumbhani
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH 44195, USA
    Am Heart J 155:640-7. 2008
    ..Accordingly, our aim was to conduct a meta-analysis to assess the benefit and safety profile of drug-eluting stents in diabetic patients...
  34. ncbi request reprint Risk of thrombosis with the use of sirolimus-eluting stents for percutaneous coronary intervention (from registry and clinical trial data)
    Anthony A Bavry
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am J Cardiol 95:1469-72. 2005
    ..Compared with bare metal stents, sirolimus-eluting stents did not appear to increase the risk for thrombosis up to 13.5 months after coronary intervention (risk ratio 0.49, 95% confidence interval 0.22 to 1.12, p = 0.09)...
  35. ncbi request reprint Effect of revascularization on mortality associated with an elevated white blood cell count in acute coronary syndromes
    Deepak L Bhatt
    Department of Cardiovascular Medicine Desk F25, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Am J Cardiol 92:136-40. 2003
    ..This finding supports a pivotal role for inflammation in acute coronary syndromes. Importantly, this study suggests that in-hospital revascularization may mitigate some of the excess risk due to inflammation...
  36. ncbi request reprint Symptomatic patients have similar outcomes compared with asymptomatic patients after carotid artery stenting with emboli protection
    Michael H Yen
    Departm, ent of Cardiovascular Nedicine F25, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Am J Cardiol 95:297-300. 2005
    ..Unlike surgical revascularization, symptomatic patients did not have a greater risk for stroke and death compared with asymptomatic patients after CAS with EPDs...
  37. ncbi request reprint Association between admission white blood cell count and one-year mortality in patients with acute coronary syndromes
    Michael H Yen
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am J Med 115:318-21. 2003
  38. ncbi request reprint Impact of female sex on outcome after percutaneous coronary intervention
    John H Chiu
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am Heart J 148:998-1002. 2004
    ..Prior reports have suggested that women have increased mortality compared to men following percutaneous coronary intervention (PCI). It remains unclear if this difference is secondary to sex or other confounding variables...
  39. doi request reprint Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis
    Dharam J Kumbhani
    Division of Cardiovascular Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA, USA
    Eur Heart J 34:1204-14. 2013
    ....
  40. doi request reprint Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51
    C Michael Gibson
    Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    J Am Coll Cardiol 62:286-90. 2013
    ....
  41. doi request reprint Intravenous platelet blockade with cangrelor during PCI
    Deepak L Bhatt
    VA Boston Healthcare System and Brigham and Women s Hospital, Boston, MA 02132, USA
    N Engl J Med 361:2330-41. 2009
    ..Intravenous cangrelor, a rapid-acting, reversible adenosine diphosphate (ADP) receptor antagonist, might reduce ischemic events during percutaneous coronary intervention (PCI)...
  42. doi request reprint Effect of platelet inhibition with cangrelor during PCI on ischemic events
    Deepak L Bhatt
    VA Boston Healthcare System, Brigham and Women s Hospital, and Harvard Medical School, Boston, MA 02132, USA
    N Engl J Med 368:1303-13. 2013
    ..Cangrelor is a potent intravenous adenosine diphosphate (ADP)-receptor antagonist that acts rapidly and has quickly reversible effects...
  43. ncbi request reprint The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study
    Deepak L Bhatt
    VA Boston Healthcare System, Brigham and Women s Hospital, and Harvard Medical School, 1400 VFW Parkway, Boston, MA 02132, USA
    Eur Heart J 33:2143-50. 2012
    ..We sought to determine the impact of CYP2C19 polymorphisms on ischaemic and bleeding events...
  44. doi request reprint Sex differences in in-hospital mortality in acute decompensated heart failure with reduced and preserved ejection fraction
    EILEEN M HSICH
    College of Medicine, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Am Heart J 163:430-7, 437.e1-3. 2012
    ..Other registries that compared patients with reduced and preserved EF did not analyze their data by sex. We sought to evaluate sex/EF differences in mortality and risk factors for survival in hospitalized patients with HF...
  45. ncbi request reprint Bare metal stent restenosis is not a benign clinical entity
    Michael S Chen
    The Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Am Heart J 151:1260-4. 2006
    ..We hypothesized that a substantial proportion of bare metal ISR presents as acute coronary syndromes. We aimed to characterize the severity of the clinical presentation of ISR...
  46. ncbi request reprint The interaction of vascular inflammation and chronic kidney disease for the prediction of long-term death after percutaneous coronary intervention
    Robert B Fathi
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Am Heart J 150:1190-7. 2005
    ..We sought to assess the relationship among glomerular filtration rate (GFR), systemic inflammation, and long-term death after PCI...
  47. ncbi request reprint Peroxisome proliferator-activated receptor gamma agonists for the Prevention of Adverse events following percutaneous coronary Revascularization--results of the PPAR study
    Deepak L Bhatt
    Cleveland Clinic, Department of Cardiovascular Medicine, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Am Heart J 154:137-43. 2007
    ..We sought to determine whether peroxisome proliferator-activated receptor gamma agonists had any beneficial effect on patients with metabolic syndrome undergoing percutaneous coronary intervention (PCI)...
  48. ncbi request reprint Incremental effect of clopidogrel on important outcomes in patients with cardiovascular disease: a meta-analysis of randomized trials
    Thomas J Helton
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio, USA
    Am J Cardiovasc Drugs 7:289-97. 2007
    ..To quantify the impact of clopidogrel plus aspirin on the individual outcomes of death, myocardial infarction, or stroke in patients with established cardiovascular disease, or in patients with multiple risk factors for vascular disease...
  49. doi request reprint Drug-eluting versus bare-metal stents for treating saphenous vein grafts
    Mehdi H Shishehbor
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH 44114, USA
    Am Heart J 158:637-43. 2009
    ..Current data show conflicting results regarding safety and efficacy of drug-eluting stents (DES) versus bare-metal stents (BMS) for treating saphenous vein grafts (SVG). Our objective was to compare DES with BMS for SVG intervention...
  50. doi request reprint Drug-eluting stent fracture and acute coronary syndrome
    Adnan K Chhatriwalla
    Division of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Cardiovasc Revasc Med 10:166-71. 2009
    ..Coronary stent fracture is an underrecognized entity but has been reported more frequently in the drug-eluting stent (DES) era. Nevertheless, the clinical implications of coronary stent fracture remain unclear...
  51. ncbi request reprint Issues in the management of antiplatelet therapy in patients undergoing surgical revascularization. A roundtable discussion
    Deepak L Bhatt
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, 9500 Euclid Avenue, Desk F25, Cleveland, OH, 44195, USA
    J Invasive Cardiol 17:283-7. 2005
  52. doi request reprint Impact of drug-eluting versus bare-metal stents on mortality in patients with anemia
    Mehdi H Shishehbor
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio 44195 0002, USA
    JACC Cardiovasc Interv 2:329-36. 2009
    ..Our aim was to assess the incidence of all-cause mortality in patients with anemia undergoing percutaneous coronary intervention (PCI) receiving drug-eluting stents (DES) or bare-metal stents (BMS)...
  53. ncbi request reprint Prediction of death or myocardial infarction by exercise single photon emission computed tomography perfusion scintigraphy in patients who have had recent coronary artery stenting
    Vivek Rajagopal
    Department of Cardiovascular, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am Heart J 149:534-40. 2005
    ..We sought to determine if exercise nuclear testing provides independent prognostic information in patients after coronary stenting...
  54. ncbi request reprint Relation of an elevated white blood cell count after percutaneous coronary intervention to long-term mortality
    Vivek Rajagopal
    The Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Am J Cardiol 94:190-2. 2004
    ....
  55. doi request reprint Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial
    Steven E Nissen
    Department of Cardiovascular Medicine and Cleveland Clinic Lerner School of Medicine, Cleveland, Ohio, USA
    JAMA 299:1547-60. 2008
    ..Abdominal obesity is associated with metabolic abnormalities and increased risk of atherosclerotic cardiovascular disease. However, no obesity management strategy has demonstrated the ability to slow progression of coronary disease...
  56. doi request reprint Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial
    Stephen D Wiviott
    Cardiovascular Division, Brigham and Women s Hospital, TIMI Study Group, Harvard Medical School, Boston, MA, USA
    Lancet 382:605-13. 2013
    ..We assessed outcomes from the TRILOGY ACS trial based on whether or not patients had coronary angiography before treatment was chosen...
  57. doi request reprint Rivaroxaban in patients with a recent acute coronary syndrome
    Jessica L Mega
    Thrombolysis in Myocardial Infarction Study Group, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 366:9-19. 2012
    ..Since factor Xa plays a central role in thrombosis, the inhibition of factor Xa with low-dose rivaroxaban might improve cardiovascular outcomes in patients with a recent acute coronary syndrome...
  58. doi request reprint Trends in smoking cessation counseling: experience from American Heart Association-get with the guidelines
    Pei Hsiu Huang
    Division of Cardiovascular Medicine, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Clin Cardiol 35:396-403. 2012
    ..Using data from GWTG, we examined trends associated with the smoking-cessation counseling (SCC) performance measure...
  59. ncbi request reprint Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial
    Deepak L Bhatt
    Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Am Heart J 148:263-8. 2004
    ..Whether dual antiplatelet therapy is superior to aspirin monotherapy for high-risk primary prevention and secondary prevention is unknown...
  60. doi request reprint Safety and efficacy of overlapping sirolimus-eluting versus paclitaxel-eluting stents
    Mehdi H Shishehbor
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH 44195, USA
    Am Heart J 155:1075-80. 2008
    ..The short-term and long-term safety and efficacy of paclitaxel versus sirolimus-overlapping drug-eluting stents (DES) is unknown. We sought to examine the clinical consequences of overlapping sirolimus versus paclitaxel DES...
  61. ncbi request reprint Clinical aspects of platelet inhibitors and thrombus formation
    Telly A Meadows
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH 44195, USA
    Circ Res 100:1261-75. 2007
    ..The use of more refined agents in conjunction with a better understanding of their effects will further the ability to provide more optimized care on an individual basis...
  62. ncbi request reprint Long-term benefit of statin therapy initiated during hospitalization for an acute coronary syndrome: a systematic review of randomized trials
    Anthony A Bavry
    Department of Cardiovascular Medicine, Cardiac, Peripheral, and Carotid Intervention, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Am J Cardiovasc Drugs 7:135-41. 2007
    ..This study sought to determine if the initiation of statin (HMG-CoA reductase inhibitor) therapy during acute coronary syndromes reduces long-term mortality and other adverse cardiac outcomes...
  63. doi request reprint Safety and efficacy of carotid stenting in individuals with concomitant severe carotid and aortic stenosis
    Subrata Kar
    Department of Internal Medicine, Cleveland Clinic, Ohio, USA
    EuroIntervention 6:492-7. 2010
    ..Carotid artery stenting (CAS) prior to open-heart surgery may be a useful approach to minimise the risk of neurologic events in patients undergoing aortic valve replacement (AVR)...
  64. doi request reprint Platelet aspirin resistance in ED patients with suspected acute coronary syndrome
    Jonathan Glauser
    Cleveland Clinic, Case Western Reserve University, Cleveland, OH 44195, USA
    Am J Emerg Med 28:440-4. 2010
    ..The prevalence of emergency department (ED) platelet aspirin resistance in suspected acute coronary syndrome (ACS) is not described. Our purpose was to determine the prevalence of platelet aspirin resistance...
  65. ncbi request reprint Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative
    Deepak L Bhatt
    Cleveland Clinic Foundation, Department of Cardiovascular Medicine Desk F25, Cleveland, Ohio 44195, USA
    JAMA 292:2096-104. 2004
    ....
  66. ncbi request reprint Feasibility of simultaneous bilateral carotid artery stenting
    Michael S Chen
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Catheter Cardiovasc Interv 61:437-42. 2004
    ..There were no procedural deaths, myocardial infarctions, or strokes. Thus, among carefully selected patients, simultaneous bilateral carotid artery stenting is a promising, technically feasible option...
  67. ncbi request reprint GuardWire emboli protection device is associated with improved myocardial perfusion grade in saphenous vein graft intervention
    Jose E Exaire
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am Heart J 148:1003-6. 2004
    ..We sought to analyze TMP after SVG-PCI with and without EPD and determine its impact on inhospital MACE...
  68. doi request reprint Long-term impact of drug-eluting stents versus bare-metal stents on all-cause mortality
    Mehdi H Shishehbor
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio 44195, USA
    J Am Coll Cardiol 52:1041-8. 2008
    ..Our purpose was to examine the incidence of all-cause mortality among drug-eluting stents (DES) and bare-metal stents (BMS) while adjusting for many confounding factors generally not considered in prior studies...
  69. ncbi request reprint Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials
    Anthony A Bavry
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am J Med 119:1056-61. 2006
    ..Drug-eluting stents are commonly used for percutaneous coronary intervention. Despite excellent clinical efficacy, the association between drug-eluting stents and the risk for late thrombosis remains imprecisely defined...
  70. ncbi request reprint Benefit of early invasive therapy in acute coronary syndromes: a meta-analysis of contemporary randomized clinical trials
    Anthony A Bavry
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio 44195, USA
    J Am Coll Cardiol 48:1319-25. 2006
    ..This study sought to systematically determine whether early invasive therapy improves survival and reduces adverse cardiovascular events in the management of non-ST-segment elevation acute coronary syndromes...
  71. ncbi request reprint Clinical trials update from the annual scientific session of the American College of Cardiology 2006
    Christopher P Cannon
    Thrombolysis in Myocardial Infarction Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    Am J Cardiol 98:36Q-41Q. 2006
  72. ncbi request reprint Using statins to treat inflammation in acute coronary syndromes: Are we there yet?
    Mehdi H Shishehbor
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Cleve Clin J Med 73:760-6. 2006
    ..In all the studies, the benefit correlated with reductions in CRP...
  73. doi request reprint Clinical outcomes using a platelet function-guided approach for secondary prevention in patients with ischemic stroke or transient ischemic attack
    Jeremiah P Depta
    VA Boston Healthcare System, 1400 VFW Parkway, Boston, MA 02132, USA
    Stroke 43:2376-81. 2012
    ..We studied the clinical outcomes associated with platelet function-guided modifications in antiplatelet therapy in patients with ischemic stroke or transient ischemic attack...
  74. ncbi request reprint Mortality benefit of beta-blockade after successful elective percutaneous coronary intervention
    Albert W Chan
    Section of Interventional Cardiology, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    J Am Coll Cardiol 40:669-75. 2002
    ..The goal of this study was to evaluate the mortality benefit of beta-blockers after successful percutaneous coronary intervention (PCI)...
  75. ncbi request reprint Thrombin, an ideal target for pharmacological inhibition: a review of direct thrombin inhibitors
    Hitinder S Gurm
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Am Heart J 149:S43-53. 2005
  76. ncbi request reprint Percutaneous coronary intervention in diabetics
    Juhana Karha
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Rev Endocr Metab Disord 5:277-85. 2004
  77. ncbi request reprint Antiplatelet agents in patients undergoing percutaneous coronary intervention: how many and how much?
    Brendan Duffy
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am J Cardiovasc Drugs 5:307-18. 2005
    ..A better understanding of our patients' overall risk will add to procedural success and more durable outcomes...
  78. ncbi request reprint Quality of acute myocardial infarction care and outcomes in 33,997 patients aged 80 years or older: findings from Get With The Guidelines-Coronary Artery Disease (GWTG-CAD)
    Hector M Medina
    Cardiac MR, PET, CT Program, Department of Radiology, Division of Cardiology, Massachusetts General Hospital, Boston, USA
    Am Heart J 162:283-290.e2. 2011
    ..To determine the adherence to national guidelines and in-hospital mortality of older patients with acute myocardial infarction (AMI) using a national database...
  79. ncbi request reprint Aspirin and clopidogrel resistance: an emerging clinical entity
    Thomas H Wang
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Eur Heart J 27:647-54. 2006
    ....
  80. doi request reprint Clopidogrel with or without omeprazole in coronary artery disease
    Deepak L Bhatt
    Veterans AffairsBoston Healthcare System, Brigham and Women s Hospital, Boston, MA 02132, USA
    N Engl J Med 363:1909-17. 2010
    ..Recently, concerns have been raised about the potential for PPIs to blunt the efficacy of clopidogrel...
  81. ncbi request reprint Presence of carotid and peripheral arterial disease in patients with left main disease
    Aaron L Doonan
    Department of Internal Medicine, Cleveland Clinic, Cleveland, Ohio, USA
    Am J Cardiol 100:1087-9. 2007
    ..In conclusion, compared with patients without LM disease, patients with LM disease have a higher burden of advanced atherosclerosis as evidenced by a higher prevalence of significant carotid stenosis and lower ankle-brachial indexes...
  82. ncbi request reprint Comparative benefits of clopidogrel and aspirin in high-risk patient populations: lessons from the CAPRIE and CURE studies
    Jack Hirsh
    The Henderson Research Centre, Hamilton, Ontario, Canada
    Arch Intern Med 164:2106-10. 2004
    ..High-risk groups in the CAPRIE and CURE studies would be expected to derive enhanced benefit from treatment with clopidogrel over that achieved by ASA...
  83. ncbi request reprint Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus
    Deepak L Bhatt
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am J Cardiol 90:625-8. 2002
  84. ncbi request reprint The Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) study: to what extent should the results be generalizable?
    Gregory P Gerschutz
    Department of Cardiology, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am Heart J 145:595-601. 2003
    ..Increased bleeding and greater requirements for blood transfusions were seen with clopidogrel. The addition of clopidogrel to aspirin represents a major advance in the treatment of acute coronary syndromes...
  85. ncbi request reprint Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events
    Peter A Ringleb
    Department of Neurology, University of Heidelberg Medical School, Heidelberg, Germany
    Stroke 35:528-32. 2004
    ....
  86. ncbi request reprint Controversies of oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention
    Vivek Rajagopal
    Cleveland Clinic Foundation, Department of Cardiovascular Medicine, Cleveland, Ohio 44195, USA
    Semin Thromb Hemost 30:649-55. 2004
    ..This article will explore the current role of and controversies in oral antiplatelet therapy after ACS and PCI...
  87. ncbi request reprint Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting
    Deepak L Bhatt
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    J Am Coll Cardiol 39:9-14. 2002
    ..We sought to determine whether clopidogrel is at least as efficacious as ticlopidine...
  88. ncbi request reprint Aspirin resistance: more than just a laboratory curiosity
    Deepak L Bhatt
    J Am Coll Cardiol 43:1127-9. 2004
  89. ncbi request reprint Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tirofiban and ReoProGive Similar Efficacy Outcome Trial (TARGET)
    Albert W Chan
    Department of Cardiology, Ochsner Clinic Foundation, New Orleans, Louisiana, USA
    J Am Coll Cardiol 42:1188-95. 2003
    ..We sought to examine if clopidogrel treatment initiated before coronary stenting improved clinical outcomes among patients receiving aspirin and a glycoprotein (GP) IIb/IIIa inhibitor...
  90. ncbi request reprint Aspirin and clopidogrel in acute coronary syndromes: therapeutic insights from the CURE study
    Hani Jneid
    Division of Cardiology, University of Louisville, Louisville, KY, USA
    Arch Intern Med 163:1145-53. 2003
    ..Aspirin resistance can be assessed through platelet aggregometry testing, measurement of urinary thromboxane metabolites, and, possibly, genomic testing in the future...
  91. ncbi request reprint Identification of and management approaches for the high-risk patient
    Deepak L Bhatt
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am J Cardiol 98:22Q-29Q. 2006
    ..The results of the CHARISMA trial are expected to provide further information on the optimal management of patients with stable atherothrombosis with respect to both antiplatelet therapy and overall management...
  92. ncbi request reprint Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in patients after recent ischemic stroke: for the Plavix Use for Treatment of Stroke (PLUTO-Stroke) trial
    Victor L Serebruany
    HeartDrug Research Laboratories, Towson, MD 21204, USA
    Stroke 36:2289-92. 2005
    ..To determine whether clopidogrel with aspirin (C+ASA) will produce more potent platelet inhibition than aspirin alone (ASA) in patients after ischemic stroke, we conducted the Plavix Use for Treatment of Stroke trial...
  93. ncbi request reprint Enhancing reperfusion therapy for myocardial infarction with dual antiplatelet therapy: Breaking the glass ceiling
    Robert B Fathi
    Am Heart J 149:947-9. 2005
  94. ncbi request reprint Treatment disparities in the care of patients with and without diabetes presenting with non-ST-segment elevation acute coronary syndromes
    Gerard X Brogan
    Department of Emergency Medicine, New York University School of Medicine North Shore Long Island Jewish Health System, Plainview, New York 11803, USA
    Diabetes Care 29:9-14. 2006
    ..The objective of this study was to characterize treatment patterns among patients with diabetes presenting with non-ST-segment elevation (NSTE) acute coronary syndromes (ACSs)...
  95. ncbi request reprint Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease
    Steven R Steinhubl
    Division of Cardiology, University of Kentucky, Lexington, KY 40536 0200, USA
    Vasc Med 12:113-22. 2007
    ....
  96. ncbi request reprint What is the risk of stent thrombosis associated with the use of paclitaxel-eluting stents for percutaneous coronary intervention?: a meta-analysis
    Anthony A Bavry
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    J Am Coll Cardiol 45:941-6. 2005
    ..This study investigated the risk of stent thrombosis associated with the use of paclitaxel-eluting stents (PES) compared to bare-metal stents (BMS)...
  97. ncbi request reprint Drug-eluting stents: dual antiplatelet therapy for every survivor?
    Anthony A Bavry
    Circulation 116:696-9. 2007
  98. ncbi request reprint Intensifying platelet inhibition--navigating between Scylla and Charybdis
    Deepak L Bhatt
    N Engl J Med 357:2078-81. 2007
  99. ncbi request reprint Clopidogrel and risk for acute coronary events
    Girish R Mood
    Department of Cardiovascular Medicine, Cleveland Clinic, 9500 Euclid Avenue, Desk F25, Cleveland, OH 44195, USA
    Curr Atheroscler Rep 9:401-8. 2007
    ..In this article, we review the benefits of clopidogrel as an antiplatelet agent and its role in the management of acute coronary syndromes and following percutaneous coronary intervention...
  100. ncbi request reprint Impaired myocardial perfusion score and inflammatory markers in patients undergoing primary angioplasty for acute myocardial infarction
    J Emilio Exaire
    Instituto Nacional de Cardiologia, Mexico City, Mexico
    Arch Cardiol Mex 76:376-82. 2006
    ....
  101. doi request reprint Clopidogrel and aspirin versus aspirin alone for the prevention of stroke in patients with a history of atrial fibrillation: subgroup analysis of the CHARISMA randomized trial
    Robert G Hart
    Department of Neurology, University of Texas Health Science Center, San Antonio, TX 78229 3900, USA
    Cerebrovasc Dis 25:344-7. 2008
    ..Aspirin offers modest reduction in stroke in patients with atrial fibrillation. Whether combination of aspirin with clopidogrel offers additional protection is unclear...